Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Drug combo aims to stop Post-Birth bleeding, but trial stopped early

NCT ID NCT01113229

First seen Mar 08, 2026 · Last updated Jun 20, 2026 · Updated 15 times

Summary

This study tested whether giving two drugs—oxytocin and misoprostol—together could prevent postpartum hemorrhage (heavy bleeding) after vaginal birth better than oxytocin alone. The trial planned to include over 1,700 women giving birth at 36 to 42 weeks, but it was terminated early, so we don't have full results. The goal was to reduce the number of women losing more than 500 mL of blood within an hour of delivery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMORRHAGE; COMPLICATING DELIVERY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Chi Poissy St Germain

    Poissy, 78300, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

oxytocin and misoprostol

What this could lead to

If it worked, this combination could offer a better way to prevent dangerous bleeding after childbirth, saving lives and reducing complications.

What could go wrong

The trial was terminated early, so results are incomplete. The combination may not be more effective than oxytocin alone and could carry added side effects like nausea or fever.

Conditions

The condition(s) this trial relates to.

Hemorrhage Postpartum Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.